14-3-3ζ
|
Increased
|
Impair antitumor function
|
Inhibit the antitumor functions of TILs and the vitality and proliferation of peripheral blood CD3+ T cells
|
[55]
|
MICA*008
|
Increased
|
Impair cytotoxic function
|
Induce NKG2D downregulation on NK cell surface
|
[58]
|
HCC antigens
|
Increased
|
Promote immune responses
|
Activate immune response mediated by DCs
|
[59]
|
Not mentioned
|
Unvaried
|
Regulate immunosuppression
|
Alter the immunosuppressive status through STAT3 pathway in macrophages
|
[62]
|
miR-490
|
Increased
|
Inhibit metastasis
|
Mast cells are stimulated by HCV-E2 and secrete exosomes to inhibit the ERK1/2 pathway
|
[63]
|
miR-142, miR-223
|
Increased
|
Inhibit proliferation
|
Decrease reporter protein expression and endogenously express stathmin-1 and insulin-like growth factor-1 receptor
|
[64]
|
linc-RoR
|
Increased
|
Regulate energy metabolism
|
Activate microRNA-145/HIF-1α/PDK1 pathway and enhance the glycolysis process
|
[65]
|
| |
Induce chemoresistance
|
Activate TGF-β signaling and promote colony formation of CD133+ T-IC
|
[66]
|
miRNA
|
Increased
|
Promote migration and invasion
|
Induce TGF-β and TAK1 expression
|
[12]
|
miR-155
|
Increased
|
Promote formation and development
|
Promote inflammation and positively correlate with IL-6 or IL-8 levels
|
[67]
|
miR-1247-3p
|
Increased
|
Promote metastasis
|
Target B4GALT3 and activate β1-integrin–NF-κB pathway
|
[50]
|
miR-30a
|
Decreased
|
Promote proliferation and metastasis
|
Mediate Beclin 1 and Atg5-dependent autophagy
|
[68]
|
miR-320a
|
Decreased
|
Promote metastasis
|
Target PBX3 and MAPK pathway, induce EMT, and upregulate CDK2 and MMP-2 expression
|
[69]
|
miR-122
|
Decreased
|
Promote proliferation
|
IGF1 prevents intercellular exosomal transfer of miR-122
|
[70]
|
|
Increase
|
Induce chemosensitivity
|
Induce chemosensitivity (5-FU and sorafenib)
|
[71]
|
miR-9-3p
|
Decreased
|
Promote proliferation
|
Regulate HBGF-5 and ERK1/2 expression
|
[72]
|
VASN
|
Increased
|
Promote HUVECs cells migration
|
Not mentioned
|
[73]
|
RNAs, miRNAs
|
Polytropic
|
Associated with the degree of lumen formation
|
Not mentioned
|
[74]
|
miR-210-3p
|
Increased
|
Increase angiogenesis
|
Inhibit the expression of SMAD4 and STAT6 in ECs
|
[75]
|
lincRNA H19
|
Increased
|
Increase angiogenesis
|
Increase VEGF release and the production of VEGF-R1
|
[76]
|
miR-221
|
Increased
|
Increase angiogenesis
|
Activate SAND/NF-κB pathway and upregulate CXCL16 expression
|
[77, 78]
|
miR-21
|
Increased
|
Increase angiogenesis
|
Activate the STAT3/VEGF pathway
|
[77, 79]
|
Not mentioned
|
Not mentioned
|
Induce chemoresistance
|
Activate HGF/c-Met/Akt pathways and restrain apoptosis
|
[80]
|
Fibronectin1 COL2A1, FGG
|
Increased
|
Promote metastasis
|
Induce either partial or total EMT
|
[81]
|
RNAs, proteins
|
Polytropic
|
Promote migration and invasion
|
Activate PI3K/AKT and MAPK pathways in MIHA and increase MMP-2 and MMP-9 secretion
|
[82]
|
miR-103
|
Increased
|
Promote metastasis
|
Inhibit the expression of VE-Cad, p120, and ZO-1
|
[83]
|
AFP
|
Increased
|
Promote immune responses; Inhibit proliferation
|
Enhance CD8+ T lymphocytes response, improve IFN-γ and IL-2 expression
|
[84]
|
HSP
|
Increased
|
Promote immune responses
|
Improve tumor immunogenicity and induce NK cell responses
|
[85]
|
PD-L1
|
Increased
|
Promote proliferation
|
Suppress T cell activation in the draining lymph node
|
[86]
|
miR-26a
|
Increased
|
Inhibit proliferation
|
Bind to HepG2 cells via the scavenger receptor class B type 1-Apo-A1 complex
|
[87]
|
Doxorubicin
|
Increased
|
Inhibit proliferation
|
imDCs were engineered to express Lamp2b fused with v integrin-specific iRGD peptide
|
[88]
|
lincRNA-VLDLR
|
Increased
|
Induce chemoresistance
|
Increase ABCG2 expression and restrain apoptosis
|
[89]
|